Plus Therapeutics Inc (PSTV) concluded trading on Thursday at a closing price of $1.38, with 353.23 million shares of worth about $487.45 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -13.21% during that period and on March 20, 2025 the price saw a gain of about 170.06%. Currently the company’s common shares owned by public are about 5.90M shares, out of which, 5.75M shares are available for trading.
Stock saw a price change of 83.98% in past 5 days and over the past one month there was a price change of 15.00%. Year-to-date (YTD), PSTV shares are showing a performance of 20.00% which decreased to -19.77% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.24 but also hit the highest price of $2.67 during that period. The average intraday trading volume for Plus Therapeutics Inc shares is 8.81 million. The stock is currently trading 51.02% above its 20-day simple moving average (SMA20), while that difference is up 26.41% for SMA50 and it goes to -1.18% lower than SMA200.
Plus Therapeutics Inc (NASDAQ: PSTV) currently have 5.90M outstanding shares and institutions hold larger chunk of about 11.50% of that.
The stock has a current market capitalization of $16.26M and its 3Y-monthly beta is at 0.97. It has posted earnings per share of -$2.24 in the same period. It has Quick Ratio of 0.44. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PSTV, volatility over the week remained 71.73% while standing at 55.48% over the month.
Stock’s fiscal year EPS is expected to rise by 70.05% while it is estimated to increase by 66.93% in next year. EPS is likely to shrink at an annualized rate of 55.25% for next 5-years, compared to annual growth of 68.20% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by D. Boral Capital on March 17, 2025 offering a Buy rating for the stock and assigned a target price of $9 to it. Coverage by Ladenburg Thalmann stated Plus Therapeutics Inc (PSTV) stock as a Buy in their note to investors on January 25, 2021, suggesting a price target of $8 for the stock.
